Vivoryon Therapeutics AG (GB:0R3M) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Vivoryon Therapeutics N.V., a clinical stage biotechnology company, has announced the successful completion of its share capital reduction from EUR 1.00 to EUR 0.01 per share, a move aimed at enhancing the company’s financial agility. This strategic step, approved by shareholders and unopposed in the creditor opposition procedure, is expected to facilitate new financing, M&A activities, and the granting of equity awards. The reduction amount has been transferred to the company’s distributable reserves, with no change in the total number of shares issued.
For further insights into GB:0R3M stock, check out TipRanks’ Stock Analysis page.